Humacyte (NASDAQ:HUMA) Stock Price Breaks Below 50 Day Moving Average – Here’s Why

Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $0.49 and traded as low as $0.4444. Humacyte shares last traded at $0.4450, with a volume of 5,769,439 shares traded.

Analyst Ratings Changes

A number of research firms have weighed in on HUMA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research note on Friday, October 2nd. Cantor Fitzgerald set a $1.00 price objective on shares of Humacyte in a research note on Thursday, November 12th. BTIG Research reaffirmed a “buy” rating and set a $2.00 price objective on shares of Humacyte in a report on Tuesday, November 10th. Barclays raised their price objective on shares of Humacyte from $0.50 to $0.60 and gave the stock an “equal weight” rating in a report on Wednesday, November 11th. Finally, Williams Trading set a $1.00 target price on shares of Humacyte in a research note on Friday, October 16th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.48.

View Our Latest Stock Analysis on HUMA

Humacyte Stock Down 18.0%

The firm has a market cap of $123.62 million, a price-to-earnings ratio of -1.01 and a beta of 2.64. The business’s 50-day moving average is $0.49 and its 200-day moving average is $0.77. The company has a debt-to-equity ratio of 3.65, a quick ratio of 3.11 and a current ratio of 3.34.

Hedge Funds Weigh In On Humacyte

Several institutional investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. acquired a new position in Humacyte in the second quarter worth $4,700,000. BlackRock Inc. acquired a new position in Humacyte during the 2nd quarter worth about $3,777,000. Marshall Wace LLP lifted its position in Humacyte by 1,548.0% during the 3rd quarter. Marshall Wace LLP now owns 2,996,553 shares of the company’s stock worth $1,558,000 after buying an additional 2,814,722 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Humacyte during the 2nd quarter worth about $785,000. Finally, HBK Investments L P bought a new stake in Humacyte during the 2nd quarter worth about $617,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

Further Reading

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.